ASTRAZENECA APPOINTS MARC DUNOYER AS EXECUTIVE VICE PRESIDENT, GLOBAL PORTFOLIO & PRODUCT STRATEGY
AstraZeneca today announced that Marc Dunoyer is to join the company in the newly created role of Executive Vice President, Global Portfolio & Product Strategy.
Marc will be responsible for driving business strategy, including business development, mergers and acquisitions, portfolio and product strategies. His most critical priorities will be to bolster the core growth platforms and therapy areas through well executed business development initiatives and leadership of internal efforts.
Marc will join AstraZeneca from GlaxoSmithKline (GSK) where, as Global Head of Rare Diseases, he established an integrated global capability in treatments for rare diseases from R&D through to commercialisation. He is also Chairman of GSK Japan and a member of the Corporate Executive Team. Previously at GSK he was President for Asia Pacific and Japan. Prior to joining GSK in 1999, Marc held a number of international positions in operations and general management at Hoechst Marion Roussel.
“I’m delighted Marc is joining us in this pivotal new role aimed at bringing greater integration across our R&D, commercial and business development activities,” said Pascal Soriot, Chief Executive Officer, AstraZeneca. “Marc is a first-rate leader with a proven track record in driving business growth and he brings to AstraZeneca a wealth of international operating experience, in particular in the important Asia region, combined with outstanding strategic skills.”
Marc, who will join the company in the second quarter of 2013, will report to Pascal Soriot and will be a member of AstraZeneca’s Senior Executive Team.
Marc has an MBA from the Hautes Etudes Commerciales and has a Bachelor of Law degree from Paris University. He qualified as a Junior Certified Public Accountant in France.
– ENDS –
NOTES TO EDITORS
To obtain a photograph of Marc Dunoyer please visit www.astrazeneca.com/media/photo-library or contact the media team (details below).
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com
|Esra Erkal-Paler||+44 20 7604 8030 (UK/Global)|
|Vanessa Rhodes||+44 20 7604 8037 (UK/Global)|
|Ayesha Bharmal||+44 20 7604 8034 (UK/Global)|
|Jacob Lund||+46 8 553 260 20 (Sweden)|
|James Ward-Lilley||+44 20 7604 8122||mob: +44 7785 432613|
|Karl Hård||+44 20 7604 8123||mob: +44 7789 654364|
|Colleen Proctor||+ 1 302 886 4065||mob: +1 302 373 1361|
|Ed Seage||+ 1 302 886 1842||mob: +1 302 357 4882|